Biotechnology company IsomAb has appointed Dr Philip Brainin as Chief Executive Officer as it looks to enter clinic with a treatment for chronic stable angina (CSA). 

Brainin arrives with experience in cardiovascular medicine, clinical research, and venture investing across EU and US biotechnology companies. He has previously invested in multiple early-stage therapeutics companies, advised Boards of Directors including for AnaCardio and NephroDI, and shaped corporate and business development strategies for portfolio companies. 

Brainin will now be tasked with taking IsomAb’s lead candidate, ISM-001, into clinical development. The treatment how been backed by strong preclinical data showing complete restoration of blood flow in severe ischaemic disease models, supporting the company’s goal of delivering a disease-modifying treatment for CSA. 

“With my background in cardiology, I see every day how limited our options are for patients with ischaemic disease,” Brainin said.  

“What excites me about IsomAb is that ISM-001 is not just another VEGF therapy. The pioneering mechanistic and pharmacological data generated by the team shows that IsomAb’s unique approach targeting VEGF-A165b removes the brakes on angiogenesis that are applied in ischaemic disease, allowing blood vessels to grow, remodel and create durable new arteries.  

“Once proof of concept is demonstrated in the clinic, I envisage a clear pathway for regulatory, manufacturing and commercial success.” 

The post IsomAb appoints CEO to lead development of angina treatment  appeared first on Drug Discovery World (DDW).